Top 10 Deals of 2024: Urinary Incontinence MedTech $3.7B Acquisition

This week we explore a major acquisition in a segment of women’s health that is often stigmatized yet universally experienced by women at some point in their lifetime: urinary incontinence.

Axonics Inc. (Nasdaq: AXNX), a publicly traded med-tech company developing and commercializing devices to treat urinary and bowel dysfunction, sold for $3.7B to Boston Scientific, a global leader in medical devices and therapies across cardiology, pulmonology, gastrology, oncology, neurology and urology.

Urinary incontinence, or the involuntary leakage of urine, is quite common, affecting 50% of adult women and up to 75% of women over 65. Women are more susceptible to urinary incontinence due to their unique anatomy and health experiences. Pregnancy, for example, causes hormonal changes, pressure on the bladder, and weakened pelvic floor muscles which leads to urinary incontinence in 40% of cases. Menopause is accompanied by urinary incontinence in 50% of cases, due to hormonal changes, loss of vaginal elasticity, and/or weight gain.

A leaky bladder leads to discomfort, embarrassment, and a decreased quality of life. Yet many women do not seek solutions due to stigma or treatment inaccessibility. Current treatments range from lifestyle changes (hard to maintain and ineffective) to surgery (expensive).  

There is a clear opportunity to innovate and invest in incontinence care as evinced by the unmet need, significant market size, and acquirer appetite.

Which startups are leading the charge in addressing urinary incontinence?‍

In recent years, several startups innovating in the urinary incontinence space have succeeded in securing VC funding across medtech, CPG and healthcare as a service.‍

Origin (ASV portfolio company): Series A - Brick-and-mortar clinic network providing pelvic floor physical therapy‍

Alloy: Series A - HRT prescriptions for perimenopause and menopause symptom management‍

Flyte: Series A -  Medical device for the effective treatment of stress urinary incontinence‍

Attn Grace: Seed - Skin-safe pads and products to help manage bladder leaks‍

Jude: Seed - All-natural, clinically proven supplement to treat urinary incontinence‍

Versameb AG: Series A - mRNA therapeutic to treat stress urinary incontinence

The Axonics acquisition marks a pivotal moment, signaling that meaningful innovation in urinary incontinence care is not only possible but increasingly prioritized in women’s health. We at Amboy Street Ventures are proud to be investing in this type of innovation to smash stigma, improve access to critical care and realize financial returns.

Continue Reading

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Top 10 Deals of 2026: Sun Pharma to Acquire Organon for $11.75B

Every year, Amboy Street highlights the top 10 transactions in women’s health. This year’s series starts with one of the largest women’s health mergers in history.

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Fast track our industry.
Get in touch today.